Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC by Dr. David Gerber
Author
Howard (Jack) West, MD

L-BLP25 is a MUC1 (mucin) vaccineDr. David Gerber, University of Texas-Southwestern, reviews results of the START trial of tecemotide immunotherapy for stage III unresectable NSCLC.

[powerpress]

ASCO Lung Cancer Highlights, Part 3: Immunotherapy for Stage III NSCLC Audio Podcast

Next Previous link

Previous PostNext Post

Related Content